https://pro.boehringer-ingelheim.com/kr/ 2025-02-25T08:58:13+00:00 daily 1.0 https://pro.boehringer-ingelheim.com/kr/oncology 2025-02-26T05:27:27+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic 2025-02-26T05:28:47+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory 2025-02-26T05:32:18+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/contact 2025-02-25T13:40:15+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/terms-use 2025-02-25T13:37:14+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/resources 2025-03-06T06:42:52+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/dosingae 2025-02-25T11:01:43+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/sequencing 2025-02-25T11:02:08+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/efficacy 2025-02-25T11:02:12+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/prescribing-information 2025-02-25T10:45:22+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/presentation 2025-02-25T10:48:59+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/sequencing/giotrif-real-world-practice-sequential-afatinib-followed-osimertinib-feasible 2025-02-25T11:02:24+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/linagliptin/news 2025-02-25T10:54:25+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/sequencing/giotrif-based-current-real-world-and-clinical-trial-evidences-optimal-regimen 2025-02-25T10:59:28+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/efficacy/giotrif-over-1000-published-cases-patients-uncommon-egfr-m-nsclc-treated-giotrif 2025-02-25T11:03:48+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/giotrif/safetycontent/kr-giotrif-safety-info 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/spiolto/safetycontent/kr-spiolto-safety-info 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/empagliflozin/safetycontent/kr-jardiance-safety-info 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/spiolto 2023-09-06T03:20:37+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/linagliptin 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/all-products 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/privacy 2025-03-05T14:24:51+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/resources/metabolic 2025-03-05T07:44:19+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/resources/respiratory 2025-03-05T07:51:11+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/resources/oncology 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/tiotropium-olodaterol 2023-09-22T07:09:41+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/afatinib 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/empagliflozin/practical-management-of-people-with-ckd-taking-sglt2-inhibitors 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/benefits-of-jardiance-for-chronic-kidney-disease-patients-confirmed-by-empa-kidney 2025-03-04T06:35:15+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/diabetes-treatments-covid-19-risk-factors 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/covid-19-impact-diabetic-patients 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/economic-burden-reduction-diabetic-patients-post-pandemic 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/dpp4-inhibitors-in-type-2-diabetes-with-kidney-issue 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/new-diabetes-drug-payment-standards-april-2023 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/heart-failure/bold-class-4-heart-failure-society-guidelines-revision 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/understanding-simplicity-of-linagliptin-in-type-2-diabetes 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/heart-failure/new-start-for-chronic-heart-failure-patients 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/simple-blood-suger-management-in-type-2-diabetes 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/lung-cancer/real-world-evidence-on-targeted-therapy-for-nsclc-reset 2025-07-07T05:33:16+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes/dissection-of-linagliptins-kidney-related-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empa-kidney-stepping-next-level-chronic-kidney-disease-management 2025-03-05T14:30:43+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/thr-tkr 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/spaf 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/dvtpe 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/respiratory-diseases/gold-2023-changes-part2-cs-inhalers-usage 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/respiratory-diseases/gold-2023-changes-part1-lama-laba-inhalers-role 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/all 2025-03-05T05:27:19+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/diabetes 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/heart-failure 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/kidney-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/lung-cancer 2025-07-02T05:08:03+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/insightclip/respiratory-diseases 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/videos 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/clinical-studies 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/jardiance-benefits-for-broad-range-of-patients 2025-03-04T06:39:12+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/spiolto/tiotropium-in-early-stage-chronic-obstructive-pulmonary-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/jardiance-benefits-for-broad-range-of-patients-2 2025-02-27T13:53:35+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/jardiance-benefits-for-broad-range-of-patients-3 2025-02-27T13:53:55+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/jardiance-benefits-for-broad-range-of-patients-4 2025-02-27T13:54:11+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/shorts/nephrology/world-kidney-day-2024-it-takes-2-including-u 2025-02-27T13:54:37+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/trajenta/dpp-4is-cv-safety-profiles 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/trajenta/cv-kidney-safety-profiles-linagliptin 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/spiolto/vahelva-tiotropiums-benefit-for-lung-function-in-gold-1-2 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/shorts/cardiology/faces-5-signals-on-early-detection-of-heart-failure 2025-02-27T13:55:01+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/cardiology/risk-factors-of-chronic-heart-failure 2025-02-27T13:55:19+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-ild-talk-how-do-we-monitor-patients-with-ctd-ild 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-ild-talk-how-do-we-keep-patients-on-treatment-with-nintedanib 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-talk-how-does-nintedanib-fit-in-with-background-treatments 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/jdn-for-ckd-patients-wide-spectrum-of-egfr-and-albuminuria 2025-02-27T13:55:43+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/spiolto/vahelva-tovito-study 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/ai-video-crm-benefits-of-jardiance 2025-03-04T06:38:33+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/cardiology/boehringer-ingelheim-jardiance-hf-fue-impact-3-gdmt 2025-02-27T13:56:01+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/baseline-characteristics-of-patients 2025-02-27T13:56:24+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/impact-of-the-egfr-dip-on-the-treatment-effect-of-empagliflozin-on-cv-and-kidney-outcomes 2025-02-27T13:56:40+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources/nephrology/ae-profile-across-subgroups-by-predictive-baseline-factors-for-an-empagliflozin-induced-egfr 2025-02-27T13:57:56+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/spiolto/invitation-the-9th-respiratory-xchange 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/sip-campaign-guidance 2025-02-25T13:18:55+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/hcps-role-in-ckd-management-when-to-refer 2025-02-25T12:45:01+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/pcps-role-in-dkd-management-and-when-to-refer-to-endocrinologist 2025-02-25T12:45:57+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/what-does-kidney-function-preservation-in-empa-kidney-mean-to-you 2025-02-25T12:46:46+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/Primary-and-secondary-outcomes-by-primary-kidney-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/kidney-disease-progression-outcome-by-primary-kidney-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/effect-of-empagliflozin-on-annual-rate-of-change-in-egfr-by-primary-kidney-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/uacr-and-blood-pressure-assessments-by-primary-kidney-disease 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/jardiance-hfref-reimbursement 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/glyxambi/esgliteo-1st-year-anniversary-thank-you-card 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/immunology/spevigo/spevigo-mode-of-action-video 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/egfr-mutant-nsclc-giotrif 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/young-good-ps-patients 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/patients-with-del19 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/patients-without-bm 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/giotrif-in-uncommon-egfr-evidence-treatment 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/giotrif-uncommon-egfr-clinical-study 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/giotrif-uncommon-egfr-real-world-evidence 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-patterns-of-disease-course-in-patients-with-ssc-ild 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/jardiance-acp-guideline-update 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance-acp-guideline-update 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/emprise-us-5-year-study 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-for-progressive-ild-with-hp 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties 2025-02-25T12:57:01+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/cardiology 2025-02-25T12:58:29+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/nephrology 2025-02-25T12:59:23+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/primary-care 2025-02-25T13:00:18+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/shorts 2025-02-25T13:01:28+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/all-specialties/resources 2025-02-25T13:02:35+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/cardiology/shorts 2025-02-25T13:04:00+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/cardiology/resources 2025-02-25T13:04:49+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/nephrology/shorts 2025-02-25T13:05:46+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/nephrology/resources 2025-02-25T13:06:33+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/primary-care/resources 2025-02-25T13:04:34+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/jardiance/primary-care/shorts 2025-02-25T13:03:33+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/cardiometabolic/events/prime-summit-3-2024 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/jardiance/jardiance-on-fluid-overload 2025-03-07T11:05:31+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/cta-1-baseline-characteristics-overview 2025-03-07T11:05:23+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/cta-2-primary-outcome-effects 2025-03-07T11:05:56+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/cta-3-egfr-slope-changes-overview 2025-03-07T11:05:47+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/cta-4-primary-composite-outcomes 2025-03-07T11:05:38+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/glyxambi/digital-medication-guide-esgliteo 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/jardiance/digital-medication-guide-jardiance-mono 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/jardiance/digital-medication-guide-jardiance-duo 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/offev-young-ild-expert-program-on-26-27-oct-2024 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/strategy-for-early-diagnosis-and-treatment-of-pulmonary-fibrosis-prof-lee-jh 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/glyxambi/guidance-of-jdn-family-vod 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/finearts-hf-data-readout 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/monitoring-for-ild-progression 2025-03-14T06:12:16+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/screening-ild-in-ctds 2025-03-14T06:15:07+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-esc-hfa-nt-probnp-thresholds-for-new-hf-diagnosis 2025-02-25T13:13:56+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-screening-for-cardiovascular-kidney-metabolic-syndrome 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-how-do-i-diagnose-and-manage-hfpef 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-hfpef-scoring-and-interpretation 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-comparative-sglt2i-rwe 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/ropu-cardiorenal-effects-of-empagliflozin-after-ami 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolism/jardiance/jardiance-is-the-optimal-treatment-for-ckd-patients 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/jardiance/jdn-indication-message-card 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/metabolic/empagliflozin/jdn-hfpef-reimbursement-message-card 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/cardiovascular/jardiance/jardiance-hfpef-diagnostic-algorithm 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/cardiovascular/jardiance/jardiance-hfpef-guideline 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev/ofev-as-core-of-pulmonary-fibrosis-care 2025-03-04T11:04:40+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/respiratory/ofev 2025-05-30T11:11:27+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/oncology/giotrif/sequencing/real-world-evidence-on-targeted-therapy-for-nsclc-reset 2025-07-03T05:40:44+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/accessibility-statement 2025-11-04T08:02:30+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/terms-of-use 2025-11-21T08:24:25+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/contact-us 2025-11-21T08:38:25+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/privacy-policy 2025-11-27T10:14:02+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/products/site-map 2025-11-27T11:46:11+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/testpage-1 2025-11-17T12:41:33+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-diabetes/key-clinical-data/dinamo-study-infographic 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-diabetes/educational-information/dinamo-study-result 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/ckd/educational-information/sglt2i-meta-analysis-impact-diabetes-kidney-outcomes 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/video-lecture/empulse-study-design-animation 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/key-clinical-data/empulse-trial-main-results 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-diabetes/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/key-clinical-data/infographic-empulse-main-results 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/heart-failure-disease-awareness-what-you-need-to-know 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-diabetes/video-lecture 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-diabetes/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/educational-information/hf-disease-awareness-video-hfref 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/video-lecture 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/oncology/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/oncology/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/oncology/video-lecture 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/video-lecture 2025-02-27T06:29:58+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/respiratory/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/respiratory/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/respiratory/video-lecture 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/metabolism-heart-failure/educational-information/hf-disease-awareness-video-hfpef 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/ckd/key-clinical-data/empa-kidney-result 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/video-lecture/radiologists-lecture-for-ild-Part3 2025-02-27T06:17:56+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/video-lecture/radiologists-lecture-for-ild-Part1 2025-03-06T07:20:23+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/ild/video-lecture/radiologists-lecture-for-ild-Part2 2025-03-06T07:33:29+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/ckd/key-clinical-data 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/ckd/educational-information 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/medinfo/diseases/crm/ckd/video-lecture 2025-02-25T08:49:21+00:00 0.5 https://pro.boehringer-ingelheim.com/kr/cvm-congress-2024 2025-03-07T11:47:15+00:00 0.5